Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The prescriber base has doubled for Trogarzo

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 14, 2021 9:38am

126 Views

Post# 32991808

RE:RE:RE:The prescriber base has doubled for Trogarzo

My best guess on Q1 sales is they were likely biased lower because the company forced sales to the distributor system at the end of Q4 so they could have a good Q4 sales number to support the offering with the pre-announcement of good Q4 sales. Also, we are going to have to figure out where all the cash went. It looks like they burned through around $10 million in cash in a $15 million sales quarter. So, the OO likey led to nasty Q1 sales and was done in such a terrible way because they were blowing through their cash faster than we could have thought possible. On the cash, they raised $46 million, had around $20 million at last report and now have $57 million.